The European Union’s health regulator has lifted the temporary restriction on the use of French drugmaker Valneva’s chikungunya vaccine, Ixchiq, in adults aged 65 and above, following a safety review.

Valneva (NASDAQ:VALN) said on Friday that the European Medicines Agency (EMA) has lifted the suspension on its chikungunya vaccine, Ixchiq, for adults aged 65 years and older. The EMA's safety ...

The CDC warns about the mosquito-borne chikungunya virus, which is gaining prevalence in South Asia and Europe, and affecting ...

The ANVISA decision marks the world's first approval of a chikungunya vaccine in an endemic country. VALN Price Action: VALN stock is up 0.49% at $6.28 at publication on Thursday. Read Next: ...

Valneva Announces Positive Phase 2 Results for Chikungunya Vaccine in Children Valneva says IXCHIQ ‘well tolerated’ by children ages 1-11 years ...

Just as new outbreaks of chikungunya threaten to become another epidemic, Bavarian Nordic, maker of a vaccine against the ...

Saint-Herblain (France), June 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month antibody persistence and safety data for its ...

Valneva plans to apply for EU regulatory approval in the second half of 2023. While Valneva's progress in developing a chikungunya vaccine is promising, experts suggest that more research is needed.

Saint-Herblain (France), April 16, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its presence at the forthcoming 25th World Vaccine Congress ...

Saint-Herblain (France), June 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month antibody persistence and safety data for ...

Saint-Herblain (France), June 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month antibody persistence and safety data for ...